arrow
C

Clara Natoli

poliambulatorio nuovo regina margherita
H指数:43
被引数:8,435

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting

Paner研究: 一项来自真实世界环境的HER2-positive晚期乳腺癌患者的多中心观察性研究的20年治疗结果分析

2021-11-296
OAAI
Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study
2021-09-017
PRE
MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study

基于MicroRNA的签名影响卵巢癌的临床过程和生物学: 一项miRNOmics研究

2021-07-1313
OAAI
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting

管腔型乳腺癌中性粒细胞与淋巴细胞比值 (NLR) 的预后相关性: 新辅助治疗的回顾性分析

CELLS
IF5.2
2021-07-0324
OAAI
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

ChangeHER试验中转移性乳腺癌HER2-positivity增益的预后相关性

2021-07-026
OAAI
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

HER2双重阻断治疗HER2阳性晚期乳腺癌的HER2丢失和T-DM1疗效降低: SePHER研究

2020-12-1042
OAAI
Second-line, anti-VEGF based after first-line, anti-EGFR based treatment in RAS wild-type metastatic colorectal cancer: The multicenter, retrospective, real-life SLAVE study
2020-07-010
OAAI
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events
2020-03-0195
PREAI
Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents. Results from the GIM-13 AMBRA study
2020-02-150
PRE
Triple negative (TNBC) metastatic breast cancer (MBC) patients (pts): Is chemotherapy (CHT) choice influenced by adjuvant (adj) treatments? Results from the GIM-13 AMBRA study
2020-02-150
PRE
Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting

DNA损伤和修复生物标志物在接受新辅助激素治疗的老年激素受体阳性乳腺癌患者中的预后相关性: 来自真实世界的证据

2019-08-182
OAAI
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

不同的HR表达模式显着影响转移性HER2乳腺癌的临床行为以及在现实世界环境中从新型anti-HER2药物中获益的程度

2019-08-075
OAAI
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients

外周血中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值联合预测乳腺癌患者新辅助化疗后病理完全缓解

BREAST
IF7.9
2019-04-01130
OAAI
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
2019-02-27308
OAAI
Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios

三阴性转移性乳腺癌中的Eribulin: 对当前证据的批评家解释和对未来情景的预测

2019-01-0116
OAAI